Attovia Therapeutics, Inc. (ATTO)

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Attovia Therapeutics to Participate in Upcoming Investor Conferences

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More

Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source

Attovia Therapeutics (NASDAQ:ATTO) Director Acquires $1,785,000.00 in Stock

Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Global Strategic Fund Venbio Purchases 382,352 Shares of Stock

Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Redmile Group, Llc Purchases 200,000 Shares

Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

Attovia Therapeutics Appoints John W. Smither to Board of Directors